Navigation Links
Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
Date:12/14/2007


Worldwide Rights for All Potential Uses, Excluding U.S. and Japan

No Other Existing Therapeutic Treatment for Celiac Disease

BASINGSTOKE, England and PHILADELPHIA, December 14 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announces that it has acquired the worldwide rights, excluding the U.S. and Japan, to AT-1001 from Alba Therapeutics Corporation (Alba). AT-1001 is Alba's lead inhibitor of barrier dysfunction in various gastrointestinal disorders that is currently in Phase 2 development for the treatment of Celiac disease. Shire has acquired rights to all uses for AT-1001, which may also be studied for the treatment of Crohn's disease and other indications.

Matthew Emmens, Chief Executive Officer, commented: "The licensing of AT-1001 from Alba is a natural fit to our growing portfolio of gastrointestinal products. This product will be marketed to specialist physicians and we would expect to use our existing European sales force that is currently establishing relationships and expertise in the GI area through the marketing of MEZAVANT XL."

Financial terms of the license are geared to the successful development and commercialization of the product. Shire will pay Alba an upfront license fee of $25 million and further development and sales-based milestones totalling to a maximum of $300.5M should the product reach blockbuster status. Shire will also pay royalties on net sales of the product, with tiered, single or double digit royalty rates.

Alba and Shire will form a joint development committee to monitor R&D activities of AT-1001. Alba will fund all development until AT-1001 has completed Proof of Concept, which is expected to be in the first half of 2009, after which Shire and Alba will share equally development costs under a joint development plan.

About Celiac disease:

Celiac disease is a T-cell mediated auto-immune dis
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. ATS Medical Expands Open Pivot Heart Valve Offerings
9. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
10. BioLife Solutions Expands Scientific Advisory Board
11. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2008)...erica Technologies, Inc., a,growth-stage medical ...platforms for tissue regeneration, today announced...n, meeting stringent international quality standar... certification is the standard,recognized and acc... of an,effective quality system. The company,s le...
(Date:11/19/2008)...Call/ -- PharmAthene, Inc.,(NYSE Alternext US: PI...ermeasures against biological and chemical threats... with Medison Pharma Ltd., to commercialize its,b...or advanced medical countermeasures to combat the ...ical weapons is a significant global,concern," st...
(Date:11/19/2008)...wswire-FirstCall/ -- Bavarian Nordic,has invoiced...t of USD 25,million as allowed under the RFP-3 co...s of the company,s IMVAMUNE(R) smallpox vaccine. T... submission of a clinical safety report,from a la...d subjects, which,is part of the regulatory packa...
(Date:11/19/2008)...swire-FirstCall/ -- Cyprotex are,proud to announc...he most,sensitive ion trap and triple quadrupole ... 5500 LC-MS/MS offers unparalleled sensitivity and...sitive triple quadrupole with the,world,s most se...ombines,exceptional quantitative and qualitative ...
Breaking Biology Technology:Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing 2Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing 3Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing 4PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel 2PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel 3PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel 4Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities 2Cyprotex Purchases Applied Biosystems Sciex QTRAP(R) 5500 LC-MS/MS 2
..., CypHer5 TM is a red-excited, pH-sensitiv...d maximally fluorescent at pH 5.5. It is therefore...cell surface receptors via acidic endosomal vesicl...,>In the assay, the receptor can be epitope-tag...belled with CypHer5. Alternatively, an endogenous ...
...ds: adenoviral vector ● viral transduction ...delivery, , Biological assays deve...d secondary screening as well as lead and target v...challenges. Establishing stable cell systems to ex...s takes time. In addition, cellular signaling is c...
...ds: Melanocortin • receptor binding assay &b... , Pro-melanocortins are present in high le... major peptide hormone fragments: adrenocorticotro...and β-endorphin. The various melanocyte stimu...elanocortin subtype 5) receptor. The melanocortin ...
....K. Dhulipala 1 , Rao S. Takkellapati 1 , Kate Lav..., , 1 GE Healthcare, Piscataway, NJ, USA ..., University of Cambridge, Cambridge, UK , ...is of the two most commonly used methods for ampli...s. Ligation-mediated PCR is one of several current...
Other Biology Technology:The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 2The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 3The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 4The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 5The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 6Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 2Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 3Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 4Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 5Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 6Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 7Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 8The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 2The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 3The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 4The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 5GenomiPhi: protocol for BAC amplification and fabrication of slides for array CGH 2GenomiPhi: protocol for BAC amplification and fabrication of slides for array CGH 3GenomiPhi: protocol for BAC amplification and fabrication of slides for array CGH 4
(Date:11/19/2008)...earchers at Carnegie Mellon University,s Robotics ...grants from the U.S. Department of Agriculture (US... apple growers and one is for orange growers, but ...er production costs. , The systems use sensors o...thin the orchards to gather a multitude of data ab...
(Date:11/19/2008)... by a University of Central Florida professor show.... , Associate Professor James Turkson,s compound...r tumors in tests on mice. The compounds, S3I-201...called STAT3, and researchers have observed no neg...very promising," Turkson said. "They,ve worked ver...
(Date:11/18/2008)...ewswire-FirstCall/ -- Orchid Cellmark Inc.,(Nasda...ity DNA testing services,today reported its fina... Total revenues were $14.9 million for the thir...he third quarter of 2007. The decrease in total,... a year ago was largely due,to lower revenues in ...
(Date:11/18/2008)...e University of Pittsburgh have developed a simple...d dental samples, two substances at the center of ...chnique involves a fluorescent substance that glow...dized mercury, the researchers report in the curre...Chemical Society . The intensity of the glow indic...
Breaking Biology News(10 mins):Carnegie Mellon developing automated systems to enable precision farming of apples, oranges 2Carnegie Mellon developing automated systems to enable precision farming of apples, oranges 32 new compounds show promise for eliminating breast cancer tumors 2Orchid Cellmark Reports Third Quarter 2008 Financial Results 2Orchid Cellmark Reports Third Quarter 2008 Financial Results 3Orchid Cellmark Reports Third Quarter 2008 Financial Results 4Orchid Cellmark Reports Third Quarter 2008 Financial Results 5Orchid Cellmark Reports Third Quarter 2008 Financial Results 6Orchid Cellmark Reports Third Quarter 2008 Financial Results 7Orchid Cellmark Reports Third Quarter 2008 Financial Results 8Pitt researchers use fluorescence to develop method for detecting mercury in fish 2Scientists in Japan design first optical pacemaker for laboratory research 20350 1Most developing countries ill equipped to ensure global biosafety 3A UN University 5652 1Most developing countries ill equipped to ensure global biosafety 3A UN University 5652 2Most developing countries ill equipped to ensure global biosafety 3A UN University 5652 3Weizmann Institute scientists create new nanotube structures 5650 1Weizmann Institute scientists create new nanotube structures 5650 2AUDIO from Medialink and Merck 3A Women Unite to Fight Cervical Cancer 20348 1
...emons, winner of the 2007 Ebbe Nielsen Prize in bi...seum, Sydney. The 2007 Ebbe Nielsen Prize has bee..., Sydney. The Global Biodiversity Information Faci...Ebbe Schmidt Nielsen, who was an inspirational lea...ty informatics. This is the only Prize in the worl...
...p CT scan, composite image of fossil gliding repti... are clearly visible The fossilized bones of a pr..., gliding reptile may remain forever embedded in s...at Penn State,s Center for Quantitative Imaging, t...tures are now known. , The new gliding reptile i...
...rs at the University of Missouri-Columbia are stud...bears were abundant in the state during the 18th a... extinct in Missouri since the late 19th century. ...ssouri Department of Conservation to help manage M... – Kaitlyn Faries, a senior biology and chemistry ...
...evoted husband and father is not enough to keep an...ng-lived seabird found in the Galapagos Islands of... switch mates after successfully raising a chick, ...led for publication in the journal Proceedings of ... , This is surprising because there is an advant...
Other Biology News:Australian wins prestigious prize in biodiversity informatics 2CT scan reveals ancient long-necked gliding reptile 2MU researchers to study the status of black bears in Missouri 2Study investigates 'divorce' among Galapagos seabirds 2
p38 MAP Kinase gamma Antibody Shipping Temperature: HOT Storage Temperature: -20C
Chicken polyclonal to HAGH ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to N terminal amino acids 110-260 of Human HAGH. Entrez GeneID: 3029 Swiss
Anti-FLIPgamma / delta (CT) Antibody, Unconjugated from QED Bioscience Inc.
Phospho- (Ser) 14-3-3 Binding Motif (4E2) Mouse mAb
Biology Products: